A Randomized Study Comparing Imatinib And Imatinib/Pegylated Interferon Alpha-2B in Newly Diagnosed Non-high Risk Chronic Myeloid Leukemia Patients in Complete Hematological Remission After Imatinib Induction Therapy

NCT01227356 Phase 2 COMPLETED

Patients with chronic myeloid leukemia in imatinib induced CHR are randomized between imatinib 400 mg daily and imatinib 400 mg daily + PegIntron 30 ug weekly. Primary endpoint: To compare at 12 months between the treatment arms the rate of Major Molecular Response (=99,9% tumour reduction) at 12 months

Details

Lead sponsor	Uppsala University
Phase	Phase 2
Status	COMPLETED
Enrolment	112
Start date	2004-09
Completion	2009-11

Conditions

• Health Care Quality
• Health Care Evaluation

Interventions

• imatinib and pegylated interferon

Primary outcomes

• Comparison of rate Major Molecular Response between treatment arms — 2004 - 2009
  Molecular response

Countries

Sweden